More than 30 branded biologics with sales of $51 billion set to lose patent exclusivity between 2011 and 2015, and uptake of biosimilar versions will drive market growth. As a result, says market research firm Datamonitor, the global market for biosimilars will grow from just $243 million in 2010 to $3.7 million in 2015.
Mark Hollis, health care analyst at Datamonitor, comments: “With the market shares of first-generation biologic drugs stagnating or declining, biosimilar monoclonal antibodies (MAbs) and second-generation biosimilars represent a high-value proposition for biosimilar manufacturers and key drivers for future growth.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze